StockData
ALX Oncology Holdings Inc logo

ALX Oncology Holdings Inc (ALXO) stock

ALXONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 3/30
$0.97−0.03 (-3.47%)

Close on Nov 18, 2026Market cap $134.14MP/E –Yield –

ALX Oncology price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

ALX Oncology's price to sales ratio was 34.3× on Oct 30, 2020.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2020Oct 30, 202034.3×–

More ALX Oncology figures

See a number that looks wrong?